Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 7/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | FABP4 | P15090 | 1/20 | 0.45 |
| ▸ | WDR5 | P61964 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | MYLK | Q15746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9165551 | 0.89 | ALDH1A1 (0.48) | CYP1A2CYP2A6POLBALDH1A1KMT2A | |
| SCHEMBL639426 | 0.87 | CYP1A2 (0.56) | CYP1A2CYP2A6POLBALDH1A1KMT2A | |
| SCHEMBL31456881 | 0.87 | CYP1A2 (0.56) | CYP1A2CYP2A6POLBALDH1A1KMT2A | |
| SCHEMBL10925668 | 0.84 | CYP1A2 (0.59) | CYP1A2CYP2A6POLBALDH1A1KMT2A | |
| SCHEMBL3182766 | 0.81 | CYP1A2 (0.54) | CYP1A2CYP2A6POLBALDH1A1KMT2A | |
| SCHEMBL17441666 | 0.81 | LDHA (0.62) | CYP1A2CYP2A6POLBALDH1A1KMT2A | |
| SCHEMBL15461585 | 0.81 | POLB (0.56) | CYP1A2CYP2A6POLBALDH1A1KMT2A | |
| SCHEMBL3133065 | 0.79 | CDK2 (0.46) | CYP1A2ALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL29904571 | 0.79 | CDK2 (0.46) | CYP1A2ALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7203155 | 0.77 | LDHA (0.68) | KMT2AMEN1LDHATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024891-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-01-27 | — | — | US | disclosed |
| EP-3890715-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | The Board Of Regents Of The University Of Texas System (US) | 2021-10-13 | — | — | EP | disclosed |
| WO-2021123237-A1 | 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE | Oxford Drug Design Limited (GB) | 2021-06-24 | — | — | WO | disclosed |
| WO-2020117972-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-06-11 | — | — | WO | disclosed |
| EP-3044218-B1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | UNIV TEXAS (US) | 2020-05-27 | — | — | EP | disclosed |
| US-10577344-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190135776-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2019-05-09 | — | — | US | disclosed |
| US-9856233-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-07-13 | — | — | US | disclosed |
| WO-2007108742-A1 | NOVEL TETRALINS AS 5-HT6 MODULATORS | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | WO | disclosed |
| CN-1286812-C | Bispiperidines as antithrombotic agents | LINRAH RES LAB CO LTD (FR) | 2006-11-29 | — | — | CN | disclosed |
| US-6333338-B1 | ANTICOAGULANTS, CARDIOVASCULAR DISORDERS | LABORATOIRE L. LAFON (FR) | 2001-12-25 | — | — | US | disclosed |
| CN-1312799-A | Bispiperidines as antithrombotic agents | L LAB (FR) | 2001-09-12 | — | — | CN | disclosed |
| US-5707985-A | Naphthyl-, quinolyl- and isoquinolyl- sulfonamide derivatives as cell adhesion modulators | TANABE SEIYAKU CO. LTD. (JP) | 1998-01-13 | — | — | US | disclosed |
| WO-1996040641-A1 | SULFONAMIDE DERIVATIVES AS CELL ADHESION MODULATORS | TANABE SEIYAKU CO., LTD. (JP) | 1996-12-19 | — | — | WO | disclosed |
| EP-0462179-A4 | NOVEL SULFONAMIDES AS RADIOSENSITIZERS | — | 1992-03-18 | — | — | EP | disclosed |
| EP-0462179-A1 | NOVEL SULFONAMIDES AS RADIOSENSITIZERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-12-27 | — | — | EP | disclosed |
| WO-1990009787-A1 | NOVEL SULFONAMIDES AS RADIOSENSITIZERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1990-09-07 | — | — | WO | disclosed |
| US-4517354-A | PROTECTIVE COATINGS | PLASTICS ENGINEERING COMPANY (US) | 1985-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135776-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | APC, VHL, TP53 | CYP1A2 4770/4885CYP2A6 4456/4885POLB 2145/4885 |
| US-20220024891-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | APC, VHL, KRAS | CYP1A2 3356/4885CYP2A6 2648/4885POLB 1157/4885 |
| US-20170197968-A1 | Compositions and Methods for Inhibiting BMP | BMP1, BMP2, BMPR2 | CYP1A2 3263/4885CYP2A6 3079/4885POLB 2348/4885 |
| US-10577344-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | APC, VHL, TP53 | CYP1A2 4770/4885CYP2A6 4456/4885POLB 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.